Save the Date! 3rd #HeartFailureWeekCan May 3-9 “Self-care + management in a virtual world.” Thank you?to our partners! https://t.co/d2AkWD3LLP for more info! @SCC_CCS @CACPR_1 @HeartLifeCanada @CCCnurses @HeartandStroke @SQIC_QHFS https://t.co/64fkYk3orK

Save the Date! 3rd #HeartFailureAwarenessWeekCan May 3-9 “Self-care + management in a virtual world.” Thank you?to our partners! https://t.co/KVpIDUSJ7J for more info! @SCC_CCS @CACPR_1 @HeartLifeCanada @CCCnurses @HeartandStroke @SQIC_QHFS https://t.co/PymAPkYfBR

#CREDENCE ?effects of canagliflozin on kidney, CV & safety according to a baseline Albuminuria ≤1000mg/g (?2348) 1000-3000mg/g (?1547) ≥3000mg/g (?506) ?kidney benefits▶️ consistent over a range of albuminuria levels ?greatest absolute kidney benefit in UACR ≥3000 mg/g https://t.co/bPeTzFeGCW

Save the Date! 3rd #HeartFailureAwarenessWeekCan May 3-9 “Self-care + management in a virtual world.” Thank you?to our partners! https://t.co/KVpIDUSJ7J for more info! @SCC_CCS @CACPR_1 @HeartLifeCanada @CCCnurses @HeartandStroke @SQIC_QHFS https://t.co/PymAPkYfBR

??#CCCongress @SCC_CCS is going Digital!! Join us Oct 20-23rd 2021 to celebrate ?? + ? ❤ care. More LBCT's, plen's avec @escardio + @ACCinTouch + @SCC_CCS_Trainee track. As your SPC chair I declare the Call for Science open! ➡️ https://t.co/Tz0MC8WrSu @SCC_CCS_CEO @SJOakland https://t.co/ctAW1LNrh7

Just released – @JACCJournals Health Policy Statement on CV Disease Considerations for #Covid19 vaccine prioritization from: “those with relatively higher-risk CV conditions should prioritize their receipt of the vaccine”. Read the full statement: https://t.co/C8DweUF0rZ

@CanHFSociety @HFSA @ACCinTouch @CJC_JCC @SCC_CCS @HeartandStroke @escardio @TheBHF @pumpinghearts @GlobalHeartHub @JCardFail @worldheartfed @PHSAofBC @PMunkCardiacCtr @trogersresearch https://t.co/w8pYZhfTPo

Curious about the TOP most viewed article of @CJC_JCC in the last 2 years? CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Function Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. O’Meara et al. ▶️ https://t.co/MiguzmhnqU ?? https://t.co/BL4RDnEBbR

@HFSA @ISHLT @HeartBrothers1 Thanks for having us!!! #hfchat2021 #HFWeek2021

@HFSA @HeartLifeCanada Q6/A2 #HFchat2021 of course we're continuing to add to our patient resource page as well https://t.co/KwSii6SyIt. Educational animation videos coming soon!!